Non-small-cell lung cancer
Conditions
Interventions
tumor 
Gold Standard:a modified RECIST 1.1 for immune-based therapeutics (termed iRECIST)
of 
Sponsors
Cancer Center, Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Driver gene negative (Boht EGFR and ALK are negative); 2. NSCLC patients with stage of IIIB-IV, no chemotherapy or radiotherapy before. 3. Asymptomatic brain metastasis; 4. Performance status of 0, 1 on the ECOG criteria. 5. Any one of the tumor markers is more than three times higher than the normal level, and the tumor markers include:CEA>15ng/mlCA-199>105U/mlCA-153>105 U/ml, AFP>60 ng/ml, NSE>60 ng/ml, SCCAg>7.5 ng/ml, CYFRA21-1>21 ng/ml Patient compliance that allow adequate follow-up. 6. Adequate hematologic (neutrophil count >= 1,500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit(UNL)x2.5, bilirubin level =< UNLx1.5), and renal (creatinine =< UNL) function. 7. Informed consent from patient or patient's relative.
Exclusion criteria
Exclusion criteria: 1. Patients with COPD or interstitial lung disease; 2. Patients with autoimmune disease; 3. Patients with moderate to severe infection; 4. Patients with severe uncontrolled cardiovascular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| consistency; | — |
Countries
China
Contacts
Public ContactXueqin Yang
Cancer Center, Army Medical Center of PLA
Outcome results
None listed